<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="abstract"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur Psychiatry</journal-id><journal-id journal-id-type="iso-abbrev">Eur Psychiatry</journal-id><journal-id journal-id-type="publisher-id">EPA</journal-id><journal-title-group><journal-title>European Psychiatry</journal-title></journal-title-group><issn pub-type="ppub">0924-9338</issn><issn pub-type="epub">1778-3585</issn><publisher><publisher-name>Cambridge University Press</publisher-name><publisher-loc>Cambridge, UK</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11863106</article-id><article-id pub-id-type="doi">10.1192/j.eurpsy.2024.224</article-id><article-id pub-id-type="other">O0101</article-id><article-id pub-id-type="pii">S0924933824002244</article-id><article-categories><subj-group subj-group-type="heading"><subject>Abstract</subject></subj-group><subj-group subj-group-type="section"><subject>Oral Communication</subject></subj-group></article-categories><title-group><article-title>The Phase III CONNEX programme assessing the efficacy and safety of iclepertin in patients with schizophrenia: Trial design and recruitment update</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Reuteman-Fowler</surname><given-names>C.</given-names></name><xref rid="aff0337" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Blahova</surname><given-names>Z.</given-names></name><xref rid="aff0338" ref-type="aff">
<sup>2</sup>
</xref><xref rid="cor0085" ref-type="corresp">
<sup>*</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Ikezawa</surname><given-names>S.</given-names></name><xref rid="aff0339" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Marder</surname><given-names>S.</given-names></name><xref rid="aff0340" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Falkai</surname><given-names>P.</given-names></name><xref rid="aff0341" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Krystal</surname><given-names>J. H.</given-names></name><xref rid="aff0342" ref-type="aff">
<sup>6</sup>
</xref></contrib></contrib-group><aff id="aff0337"><sup>1</sup>Boehringer Ingelheim Pharmaceuticals Inc., <city>Ridgefield</city>, <state>CT</state>, <country>United States</country></aff><aff id="aff0338"><sup>2</sup>Boehringer Ingelheim RCV GmbH &#x00026; Co. KG, <city>Vienna</city>, <country>Austria</country></aff><aff id="aff0339"><sup>3</sup><institution>The University of Tokyo</institution>, Komaba, Meguro-ku, <city>Tokyo</city>, <country>Japan</country></aff><aff id="aff0340"><sup>4</sup>David Geffen School of Medicine, <city>Los Angeles</city>, <state>CA</state>, <country>United States</country></aff><aff id="aff0341"><sup>5</sup>Ludwig Maximilians University Munich, Munich, Germany, <city>Munich</city>, <country>Germany</country></aff><aff id="aff0342"><sup>6</sup><institution>Yale University School of Medicine</institution>, <city>New Haven</city>, <state>CT</state>, <country>United States</country></aff><author-notes><corresp id="cor0085"><label>*</label>Corresponding author.</corresp></author-notes><pub-date publication-format="electronic" date-type="collection" iso-8601-date="2024-04"><month>4</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>27</day><month>8</month><year>2024</year></pub-date><volume>67</volume><issue seq="199">Suppl 1</issue><issue-title content-type="special_issue">Abstracts of the 32nd European Congress of Psychiatry</issue-title><fpage>S87</fpage><lpage>S88</lpage><permissions><copyright-statement>&#x000a9; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>The Author(s)</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (<uri xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</uri>), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="S0924933824002244a.pdf"/><abstract><sec id="sec0507"><title>Introduction</title><p>In a 12-week, Phase II (NCT02832037) trial, iclepertin (BI 425809), an inhibitor of glycine transporter-1, was generally well tolerated and significantly improved cognition in 509 patients with schizophrenia.</p></sec><sec id="sec0508"><title>Objectives</title><p>The Phase III CONNEX programme aims to confirm the efficacy, safety and tolerability of iclepertin in improving cognition and functioning across a larger cohort of patients with schizophrenia.</p></sec><sec id="sec0509"><title>Methods</title><p>The CONNEX programme includes 3 randomised, double-blind, placebo-controlled parallel group trials in patients with schizophrenia (NCT04846868, NCT04846881, NCT04860830) receiving stable antipsychotic treatment. Each trial aims to recruit &#x002dc;586 patients, 18&#x02013;50 years old, treated with 1&#x02013;2 antipsychotic medications (&#x02265;12 weeks on current drug and &#x02265;35 days on current dose before treatment) who have functional impairment in day-to-day activities and interact &#x02265;1 hour per week with a designated study partner. Patients with cognitive impairment due to developmental, neurological or other disorders, with a current DSM-5 diagnosis other than schizophrenia or receiving cognitive remediation therapy within 12 weeks prior to screening, will be excluded. Patients will be recruited from multiple centres across 41 countries in Asia, North and South America, Europe and the Asia-Pacific Region, and randomised 1:1 to receive either iclepertin 10 mg (oral administration; n=293), or placebo (n=293) once daily for 26 weeks. The primary endpoint is change from baseline in overall composite T-score of the Measurement and Treatment Research to Improve Cognition in Schizophrenia Consensus Cognitive Battery. The key secondary endpoints are change from baseline in total score on the Schizophrenia Cognition Rating Scale and change from baseline in the adjusted total time T-score in the Virtual Reality Functional Capacity Assessment Tool.</p></sec><sec id="sec0510"><title>Results</title><p>The CONNEX programme is currently recruiting (<bold>Table</bold>); the first patients were enrolled in Aug&#x02013;Sept 2021 and completion is expected in Q1 2025. The presentation will describe the current study status, information relating to screening failures, and the experience of collecting these data as part of a large multi-country, multicentre study.<table-wrap position="anchor" id="tab4"><label>Table.</label><caption><p>The number of patients recruited by 31 August 2023</p></caption><alternatives><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1"/><th align="left" valign="middle" rowspan="1" colspan="1">CONNEX 1</th><th align="left" valign="middle" rowspan="1" colspan="1">CONNEX 2</th><th align="left" valign="middle" rowspan="1" colspan="1">CONNEX 3</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>Screened</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">565</td><td align="center" valign="middle" rowspan="1" colspan="1">521</td><td align="center" valign="middle" rowspan="1" colspan="1">493</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>Randomised</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">409</td><td align="center" valign="middle" rowspan="1" colspan="1">360</td><td align="center" valign="middle" rowspan="1" colspan="1">350</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><bold>Completed trial medication</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">202</td><td align="center" valign="middle" rowspan="1" colspan="1">184</td><td align="center" valign="middle" rowspan="1" colspan="1">191</td></tr></tbody></table><graphic xlink:href="S0924933824002244-TABU0004" position="anchor"/></alternatives></table-wrap>
</p></sec><sec id="sec0511"><title>Conclusions</title><p>Iclepertin may represent the first efficacious medication for cognitive impairment associated with schizophrenia.</p></sec><sec id="sec0512"><title>Funding</title><p>Boehringer Ingelheim</p></sec><sec id="sec0513"><title>Disclosure of Interest</title><p>C. Reuteman-Fowler Employee of: Boehringer Ingelheim, Z. Blahova Employee of: Boehringer Ingelheim, S. Ikezawa Consultant of: Boehringer Ingelheim Pharma GmbH, Lundbeck, Takeda Pharma, Sumitomo Dainippon Pharma, Employee of: International University of Health and Welfare, Mita Hospital, Tokyo, Japan, S. Marder Consultant of: Boehringer Ingelheim Pharma GmbH, Merck, Biogen and Sunovion, P. Falkai Consultant of: Boehringer Ingelheim Pharma GmbH, Boehringer Ingelheim Pharma Advisory Board, J. H. Krystal Shareolder of: Freedom Biosciences, Inc., Biohaven Pharmaceuticals, Sage Pharmaceuticals, Spring Care, Biohaven Pharmaceuticals Medical Sciences, EpiVario, RBNC Therapeutics, Terran Biosciences and Tempero Bio, Consultant of: Aptinyx, Atai Life Sciences, AstraZeneca Pharmaceuticals, Biogen, Biomedisyn Corporation, Bionomics, Boehringer Ingelheim International, Cadent Therapeutics, Clexio Bioscience, COMPASS Pathways, Concert Pharmaceuticals, Epiodyne, EpiVario, Greenwich Biosciences, Heptares Therapeutics, Janssen, Jazz Pharmaceuticals, Otsuka America Pharmaceutical, Perception Neuroscience Holdings, Spring Care, Sunovion Pharmaceuticals, Takeda Industries, Taisho Pharmaceutical Co.; Biohaven Pharmaceuticals, BioXcel Therapeutics, Cadent Therapeutics, Cerevel Therapeutics, Delix Therapeutics, EpiVario, Eisai, Jazz Pharmaceuticals, Novartis, PsychoGenics, RBNC Therapeutics, Tempero Bio and Terran Biosciences Advisory Boards</p></sec></abstract><counts><page-count count="2"/></counts></article-meta></front></article>